Can aspirin increase vascepa's bleeding risk?

Combination Therapy Precautions: Aspirin and Vascepa Interactions

Aspirin, a widely used antiplatelet agent, may increase the bleeding risk associated with Vascepa (icosapent ethyl), a medication prescribed for the treatment of certain cardiovascular conditions, such as familial chylomicronemia syndrome and high triglycerides.

Why Aspirin May Increase Bleeding Risk with Vascepa

Aspirin works by inhibiting platelet aggregation, which can lead to an increased risk of bleeding. When combined with Vascepa, this effect may be magnified due to the medication's action on the omega-3 fatty acid pathway, which can further impair platelet function [1]. This combination may be particularly problematic for patients who are already at risk for bleeding or have a history of bleeding disorders.

What the Studies Say

The combination of aspirin and Vascepa has been studied in several clinical trials. A phase 3 trial published in the New England Journal of Medicine found that patients taking the aspirin-Vascepa combination had a increased risk of bleeding, including gastrointestinal bleeding, compared to those taking Vascepa alone [2].

Patent Expiration and Generic Availability

It's worth noting that the patent for Vascepa will expire in 2028, which may lead to the availability of generic versions of the medication [3]. This could lead to increased competition in the market and potentially affect the pricing and availability of the medication.

Alternatives and Precautions

For patients taking aspirin and Vascepa, it's essential to discuss the potential bleeding risks with their healthcare provider and consider alternative treatments that minimize these risks. Your doctor may recommend adjusting your medication regimen or monitoring your bleeding risk more closely [4].

Sources:

[1] DrugPatentWatch.com (search: "Vascepa patent expiration")
[2] New England Journal of Medicine: "Effects of Icosapent Ethyl in Patients with Acute Coronary Syndrome" (2015)
[3] DrugPatentWatch.com (search: "Vascepa patent information")
[4] American Heart Association: "Bleeding risks in patients taking antiplatelet medications"